OPK-88005 is under clinical development by OPKO Health and currently in Phase II for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase II drugs for Hemophilia A (Factor VIII Deficiency) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OPK-88005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OPK-88005 overview
OPK-88005 (Factor VIIa-CTP) is under development for the treatment of bleeding episodes in hemophilia A and B patients. It is administered intravenously and subcutaneously as every-other-day prophylactic treatment or twice a week regimen. It is a long acting factor VIIa fused to carboxyl terminal peptide (FVIIa-CTP).
OPKO Health overview
OPKO Health (OPKO) is a healthcare company that operates in the pharmaceutical and diagnostics sectors. The company’s main activities include the development and commercialization of medical products and services, with a focus on large and rapidly growing medical markets. OPKO’s pharmaceutical business features products such as Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, and Somatrogon, a once-weekly human growth hormone injection. The company’s diagnostics business includes BioReference Health LLC, a clinical laboratory with a core genetic testing business. OPKO’s products are used in various medical applications, including the treatment of chronic kidney disease, growth hormone deficiency, and genetic testing. The company has partnered with Pfizer Inc for the further development and commercialization of Somatrogon. OPKO operates in multiple global markets, including the US, Europe, Japan, Canada, and Australia, with established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO is headquartered in Miami, Florida, the US.
For a complete picture of OPK-88005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
